The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved the use of GSK’s momelotinib (Omjjara) for moderate to severe anaemia in adult patients with myelofibrosis.

Health Canada has granted approval for GlaxoSmithKline’s (GSK) Ojjaara (momelotinib) for treating myelofibrosis (MF) in adults with moderate-to-severe anaemia. The once-daily, oral treatment is ...

GSK's cancer unit has been given a fillip by the FDA with a broader-than-expected approval for JAK inhibitor momelotinib for anaemia associated with myelofibrosis, acquired as part of its $1.9 ...

GSK looks like it is starting to show the benefit ... vaccine Arexvy and myelofibrosis therapy Omjjara/Ojjaara (momelotinib) – both launched within the last 12 months – helped lift the company ...